ArticleJournal of translational medicine2026
Single-cell transcriptome analysis reveals DNMT1
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundLymph node (LN) metastasis is the leading cause of unfavorable prognosis in bladder cancer (BCa), which involves a highly complex tumor microenvironment. The detailed molecular mechanisms that drive BCa LN metastasis, however, are not yet fully elucidated.
methodsIn this study, single-cell transcriptomic profiling of 153,339 cells from seventeen BCa patients with or without LN metastases was analyzed. We integrated single-cell transcriptomic data and bulk RNA sequencing data, and employed multiple strategies for the analysis and identification of heterogeneity in epithelial and macrophage cells in BCa. Furthermore, mouse model and cell experiments were performed to validate and dissect the characteristics of the immunosuppressive microenvironment for LN metastases.
resultsThis study found that DNMT1+ epithelial cells, characterized by a high potential for epithelial-mesenchymal transition, exhibited a propensity for LN metastasis. Notably, a specific subpopulation of tumor-associated macrophages (TAMs), marked by selective expression of SELENOP, has been identified. Intercellular crosstalk analysis observed the CXCL signal flow directed primarily from DNMT1+ epithelials to SELENOP+ TAMs. Through both in vitro and in vivo validation, it was suggested that DNMT1 promotes the recruitment and M2-type polarization of TAMs by enhancing CXCL17 expression and secretion. Additionally, CXCL17-mediated reprogramming of TAMs is associated with increased lymphangiogenesis and LN metastasis in BCa. Mechanistically, DNMT1 was found to bind the PTP1B promoter and enhance methylation enrichment at this region, which is consistent with reduced PTP1B expression and activation of JAK2/STAT3 signaling, thereby promoting the expression and secretion of CXCL17.
conclusionsThese findings uncover key molecular mechanisms that shape the lymphatic metastatic niche and offer a foundation for novel strategies aimed at targeting pro-metastatic elements to suppress BCa progression and metastasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.